Liver toxicity of lopinavir-containing regimens in HIV-infected patients with or without hepatitis C coinfection

AIDS Research and Human Retroviruses

Volumn 20, Issue 7, 2004, Pages 698-700

  González Requena, Daniel ^a   Núñez, Marina ^a   Jiménez Nacher, Inmaculada ^a   González Lahoz, Juan ^a   Soriano, Vincent ^a,b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b NONE   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

LOPINAVIR; LOPINAVIR PLUS RITONAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; PYRIMIDINONE DERIVATIVE;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG BLOOD LEVEL; FEMALE; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION RATE; LIVER TOXICITY; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUPERINFECTION; TIME; CD4 LYMPHOCYTE COUNT; DRUG EFFECT; IMMUNOLOGY; INCIDENCE; LIVER; PATHOLOGY; VIROLOGY;

ADULT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; FEMALE; HEPATITIS C; HIV INFECTIONS; HUMANS; INCIDENCE; LIVER; MALE; PYRIMIDINONES;

EID: 3843086137     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/0889222041524562     Document Type: Article

References (23)

1. Rodríguez-Rosado R, García-Samaniego J, and Soriano V: Hepatotoxicity after introduction of highly active antiretroviral therapy. AIDS 1998;12:1256.
2. Saves M, Vandentorren S, Daucourt V, Marimoutou C, Dupon M, Couzigou P, et al.: Severe hepatic cytolysis: Incidence and risk factors in patients treated by antiretroviral combinations. Aquitaine Cohort, France, 1996-1998. AIDS 1999;13:F155-F121.
3. Sulkowski M, Thomas D, Chaisson R, and Moore R: Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
4. Den Brinker M, Wit F, Wertheim-van Dillen P, Jurriaans S, Weel J, van Leeuwen R, et al.: Hepatitis B and C virus co-infection and the risk for hepatotoxicity of highly active antiretroviral therapy in HIV-1 infection. AIDS 2000;14:2895-2902.
5. Saves M, Raffi F, Clevenbergh P, Marchou B, Waldner-Combermoux A, Morlat P, et al.: Hepatitis B or hepatitis C virus infection is a risk factor for severe hepatic cytolysis after initiation of a protease inhibitor-containing antiretroviral regimen in HIV-infected patients. Antimicrob Agents Chemother 2000:44:3451-3455.
6. Núñez M, Lana R, Mendoza J, Martín-Carbonero L, and Soriano V: Risk factors for severe hepatic injury following the introduction of HAART. J Acquir Immune Defic Syndr 2001;27:426-431.
7. Bonfanti P, Landonio S, Ricci E, Martinelli C, Fortuna P, Faggion I, and Quirino T: Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001;27:316-318.
8. D'Arminio Monforte A, Bugarini R, Pezzotti P, De Luca A, Antinori A, Mussini C, et al.: Low frequency of severe hepatotoxicity and association with HCV coinfection in HIV-positive patients treated with HAART. J Acquir Immune Defic Syndr 2001;28:114-123.
9. Aceti A, Pasquazzi C, Zechini B, De Bac C, and The LIVER-HAART Group: Hepatotoxicity development during antiretroviral therapy containing protease inhibitors in patients with HIV. The role of hepatitis B and C virus infection. J Acquir Immune Defic Syndr 2002;29:41-48.
10. Wit F, Weverling G, Weel J, Jurrians S, and Lange J: Incidence and risk factors for severe hepatotoxicity associated with antiretroviral combination therapy. J Infect Dis 2002;186:23-31.
11. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, and Snydman D: Increasing mortality due to end-stage liver disease in patients with HIV infection. Clin Infect Dis 2001;32:492-497.
12. Clark S, Creighton S, Portmann B, Taylor C, Wendon J, and Cramp M: Acute liver failure associated with antiretroviral treatment for HIV: A report of six cases. J Hepatol 2002;36:295-301.
13. Lewden C: Factors associated with mortality in HIV-infected adults initiating PI. J Infect Dis 2002;186:710-714.
14. Selik R, Byers R, and Dworkin M: Trends in diseases reported on U.S. death certificates that mentioned HIV infection, 1987-1999. J Acquir Immune Defic Syndr 2002;29:378-387.
15. Hugen P, Verweij van Wissen C, and Burger D: Simultaneous determination of the HIV protease inhibitors indinavir, nelfinavir, saquinavir and ritonavir in human plasma by reversed phase high-performance liquid chromatography. J Chromatogr B 1999;727:139-149.
16. AIDS Clinical Trials Group: Table of grading severity of adult adverse experiences. Rockville: Division of AIDS, National Institute of Allergy and Infectious Diseases, 1996.
17. Dieterich D, Fischl M, and Sepúlveda G: The safety/efficacy of protease inhibitors in hepatitis C co-infected patients. 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy, September 27-30, 2002, San Diego (Abstract H-1729).
18. González de Requena D, Núñez M, Jiménez- Nácher I, and Soriano V: Liver toxicity caused by nevirapine. AIDS 2002;16:290-291.
19. Gatti G, Di Biagio A, Casazza R, De Pascalis C, Bassetti M, Cruciani M, et al.: The relationship between ritonavir plasma levels and side-effects: Implications for therapeutic drug monitoring. AIDS 1999;13:2083-2089.
20. Burger D, Felderhof M, Phanupak P, Duncombe C, Mahanontharit A, Yeamwanichnun W, et al.: Both short-term virological efficacy and drug-associated nephrotoxicity are related to indinavir pharmacokinetics in HIV-1-infected Thai patients. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago (Abstract 730).
21. Lamotte C, Peytavin G, Perre P, Chavanet P, De Truchis P, and Gilquin J: Increasing adverse events with indinavir (IDV) dosages and plasma concentrations in four different ritonavir-IDV-containing regimens in HIV-infected patients. Program and Abstracts of the 8th Conference on Retroviruses and Opportunistic Infections, February 4-8, 2001, Chicago (Abstract 738).
22. Clevenbergh P, Garraffo R, and Durant J: Evaluation of plasma lipid abnormalities in PharmaAdapt: Relation with nature and PI or NNRTI plasma concentrations. Program and Abstracts of the 3rd International Workshop on Clinical Pharmacology of HIV Therapy, April 12-13, 2002, Washington, D.C. (Abstract 4.1).
23. Treluyer J, Morini J, Dimet J, Gorin I, Rey E, Deleuze J, et al.: High concentrations of nelfinavir as an independent risk factor for lipodystrophy in HIV-infected patients. Antimicrob Agents Chemother 2002;46:4009-4012.